8.4 Resolution of inflammation

Resolution of Acute Inflammation

Acute inflammation is meant to be temporary. Once the threat is neutralized, the immune system must actively shut down the inflammatory response, clear the damage, and restore normal tissue function. This resolution phase isn't just a passive "fading away" of inflammation; it requires coordinated molecular signals and cellular processes. When resolution fails, the result is chronic inflammation, fibrosis, and disease.

Processes of acute inflammation resolution

Resolution unfolds through several overlapping steps, roughly in this order:

1. Removal of the inflammatory stimulus. Neutrophils and macrophages eliminate pathogens through phagocytosis, while antibodies and complement proteins neutralize remaining harmful substances. Without removing the initial trigger, resolution cannot begin.

2. Clearance of cellular debris. Phagocytes engulf dead cells and tissue fragments. Matrix metalloproteinases (MMPs) break down damaged extracellular matrix components so fresh matrix can be deposited later.

3. Cessation of pro-inflammatory mediator production. Cells downregulate synthesis of cytokines (TNF-α, IL-1β, IL-6) and chemokines. Prostaglandin and leukotriene release tapers off. This is partly driven by the same lipid mediator class-switching that generates anti-inflammatory signals (see below).

4. Reversal of vascular changes. Endothelial cells repair their tight junctions, reducing vascular permeability. Normal blood flow is restored, and fluid leakage (edema) subsides.

5. Tissue repair initiation. Fibroblasts become activated and begin producing collagen to rebuild the extracellular matrix. Angiogenesis generates new blood vessels to supply the healing tissue.

Role of anti-inflammatory mediators

Resolution depends on a distinct class of lipid mediators called specialized pro-resolving mediators (SPMs). These are not simply "less inflammation"; they are active signals that drive the process forward.

• Lipoxins are derived from arachidonic acid, the same precursor that generates pro-inflammatory prostaglandins. This is a key concept: the same substrate gets redirected toward resolution. Lipoxins inhibit neutrophil recruitment and activation while promoting macrophage efferocytosis of apoptotic cells.
• Resolvins are synthesized from omega-3 fatty acids (EPA and DHA). They reduce vascular permeability and enhance macrophage phagocytosis of dying cells. The E-series resolvins come from EPA; the D-series come from DHA.
• Protectins (also called neuroprotectins in neural tissue) decrease pro-inflammatory cytokine production, particularly TNF-α and IL-1β, and promote tissue repair through fibroblast activation.
• Maresins (macrophage mediators in resolving inflammation) stimulate the macrophage phenotype switch from the pro-inflammatory M1 state to the anti-inflammatory/reparative M2 state. They also enhance tissue regeneration by promoting stem cell differentiation.

Collectively, these SPMs work by:

• Downregulating adhesion molecules on endothelium, which stops further leukocyte infiltration
• Promoting lymphatic drainage to resolve edema
• Activating local stem and progenitor cells to support tissue repair

Apoptosis and efferocytosis in inflammation

Two tightly linked cellular processes are central to resolution:

Apoptosis of activated immune cells (especially neutrophils) is essential. Neutrophils are short-lived by design. When they undergo programmed cell death rather than necrosis, they avoid releasing their toxic intracellular contents (reactive oxygen species, proteases, DAMPs) into the surrounding tissue. This limits collateral damage.

Efferocytosis is the phagocytic clearance of these apoptotic cells by macrophages. This step does more than just clean up:

• It prevents secondary necrosis, which would occur if apoptotic cells lingered and lost membrane integrity, spilling pro-inflammatory DAMPs.
• It triggers macrophages to release anti-inflammatory mediators, especially TGF-β and IL-10, which suppress further immune activation.
• Efferocytic macrophages also secrete growth factors like VEGF (promotes angiogenesis) and PDGF (stimulates fibroblast proliferation), directly linking debris clearance to tissue repair.

Beyond repair, efferocytosis contributes to immune regulation. Apoptotic cell-derived self-antigens are presented in a tolerogenic context, reinforcing self-tolerance. Regulatory T cells (Tregs) are also activated during this phase, suppressing lingering adaptive immune responses.

Consequences of impaired resolution

When any of the steps above fail, inflammation becomes self-perpetuating. The consequences escalate in severity:

• Persistent inflammation. Continued recruitment of neutrophils and macrophages, with sustained release of IL-6, TNF-α, and other pro-inflammatory mediators, creates a feed-forward loop.
• Tissue damage. Excessive reactive oxygen species (ROS) and unchecked protease activity (from MMPs and neutrophil elastase) degrade the extracellular matrix and injure healthy cells.
• Fibrosis. The body attempts repair, but in the context of ongoing inflammation, fibroblasts overproduce collagen and other matrix proteins. This disordered scarring impairs organ function. Classic examples include liver cirrhosis, pulmonary fibrosis, and cardiac fibrosis after myocardial infarction.
• Chronic inflammatory diseases. Conditions like rheumatoid arthritis, inflammatory bowel disease, and atherosclerosis all involve a failure of resolution rather than simply an excess of initial inflammation. This distinction matters therapeutically.
• Systemic effects. Chronic low-grade inflammation contributes to cardiovascular disease and metabolic dysregulation, including insulin resistance. Elevated circulating IL-6 and CRP are markers of this systemic inflammatory state.
• Autoimmune disorders. Prolonged inflammation can break self-tolerance. When cells undergo necrosis instead of orderly apoptosis and efferocytosis, intracellular antigens are exposed to the immune system, potentially triggering autoantibody production and autoimmune pathology.